Test Development and Clinical Validation Archives - Agendia Inc.

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology
Gallery
MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

BluePrint, Evidence, Journal of Molecular Diagnostics, MammaPrint, Mittempergher, Test Development, Test Development and Clinical Validation

MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology

PUBLICATION: Journal of Molecular Diagnostics September 2019 Volume 21, Issue Read More

kevin2020-06-15T17:49:00-07:00September 1st, 2019|BluePrint, Evidence, Journal of Molecular Diagnostics, MammaPrint, Mittempergher, Test Development, Test Development and Clinical Validation|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
Gallery
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

BluePrint, Evidence, Groenendijk, npj Breast Cancer, Test Development and Clinical Validation

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

kevin2020-06-15T17:56:43-07:00April 18th, 2019|BluePrint, Evidence, Groenendijk, npj Breast Cancer, Test Development and Clinical Validation|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
Gallery
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint, Evidence, Grant, South African Journal of Science, Test Development and Clinical Validation

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

kevin2020-06-15T17:58:57-07:00March 27th, 2019|BluePrint, Evidence, Grant, South African Journal of Science, Test Development and Clinical Validation|

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups
Gallery
Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

BluePrint, Breast Cancer Res Treat, Breast Cancer Research Treatment, Evidence, Test Development and Clinical Validation, Yao

Molecular Subtyping Improves Diagnostic Stratification of Patients with Primary Breast Cancer into Prognostically-Defined Risk Groups

PUBLICATION: Breast Cancer Res Treat (2015) 154: 81. https://doi.org/10.1007/s10549-015-3587-9. AUTHORS: Read More

kevin2020-06-15T18:50:26-07:00November 1st, 2015|BluePrint, Breast Cancer Res Treat, Breast Cancer Research Treatment, Evidence, Test Development and Clinical Validation, Yao|

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics
Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

BluePrint, Breast Cancer Res Treat, Evidence, Groenendijk, Test Development and Clinical Validation

Estrogen Receptor Splice Variants as a Potential Source of False-Positive Estrogen Receptor Status in Breast Cancer Diagnostics

PUBLICATION: Breast Cancer Res Treat (2013) 140:475–484 DOI 10.1007/s10549-013-2648-1 AUTHORS: Floris H. Read More

kevin2013-08-04T17:37:20-07:00August 4th, 2013|BluePrint, Breast Cancer Res Treat, Evidence, Groenendijk, Test Development and Clinical Validation|

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients
Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

Ann Surg Oncol., Annals of Surgical Oncology, BluePrint, Evidence, Nguyen, Test Development and Clinical Validation

Comparison of Molecular Subtyping with BluePrint, MammaPrint, and TargetPrint to Local Clinical Subtyping in Breast Cancer Patients

PUBLICATION: Ann Surg Oncol. 2012 Oct;19(10):3257-63. doi: 10.1245/s10434-012-2561-6. Epub 2012 Aug Read More

kevin2012-08-15T16:55:56-07:00August 15th, 2012|Ann Surg Oncol., Annals of Surgical Oncology, BluePrint, Evidence, Nguyen, Test Development and Clinical Validation|

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response
A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

BluePrint, Breast Cancer Research Treatment, Evidence, Krijgsman, Test Development and Clinical Validation

A Diagnostic Gene Profile for Molecular Subtyping of Breast Cancer Associated with Treatment Response

PUBLICATION: Breast Cancer Res Treat (2012) 133: 37. https://doi.org/10.1007/s10549-011-1683-z. AUTHORS: Oscar Krijgsman, Read More

kevin2012-05-01T22:15:54-07:00May 1st, 2012|BluePrint, Breast Cancer Research Treatment, Evidence, Krijgsman, Test Development and Clinical Validation|

agendia_logo_stacked_white_po

Quick Links

Our Tests
Resources
Landmark Trials
Order A Test
For Patients

Legal

Privacy Policy
Legal & Compliance
Terms & Conditions
Licenses & Accreditations
Code of Conduct

Contact

For the US, Puerto Rico, Canada
and South America
Agendia Inc. USA, 22 Morgan, Irvine, CA 92618
(888) 321-2732
customercare@agendia.com

For outside the Americas
Agendia NV, Radarweg 60, 1043 NT Amsterdam, The Netherlands
+31 (0)20 462 1510
customerservice@agendia.com

© 2022 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.